ESOPHAGEAL ADENOCARCINOMA

This study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…

This early-stage study tests a new drug called PF-08046876 in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. The drug is designed to stick to cancer cells and kill them directly. The main goals are to check safety, find the best dose, an…

This study tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy helps people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) w…

This study tests whether adding the blood pressure drug propranolol to standard chemoradiation is safe and effective for people with esophageal adenocarcinoma. About 106 participants will receive the combination, and researchers will monitor side effects and how long the cancer s…

This study tests whether adding itraconazole, a widely used antifungal medication, to standard chemotherapy and radiation can help eliminate more esophageal cancer before surgery. About 78 adults with resectable esophageal or gastroesophageal junction cancer will take itraconazol…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study tests whether adding a special treatment sequence (called sequential cytoreductive intervention) to standard therapy can help people with advanced upper gastrointestinal cancers that have spread but show no detectable tumor DNA in the blood. About 54 adults with cancer…

This early-stage study tests a new treatment called DISP-10 for people with advanced colorectal, stomach, or esophageal cancers that have spread. The treatment combines a virus that may help the immune system attack cancer cells with specially engineered immune cells (CAR T cells…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors, including stomach, pancreatic, and bile duct cancers. The main goals are to check the drug's safety, find the best dose, and see how the body process…

This early-phase trial tests a new treatment for people with a type of stomach or esophagus cancer that has spread to the lining of the abdomen. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The cells are given …

This early-phase study tests an experimental drug called BL-M05D1 in 160 adults with advanced or metastatic solid tumors, including stomach, pancreatic, esophageal, and bile duct cancers. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. …

This study is testing a mix of chemotherapy drugs and immunotherapy as a first treatment for people with advanced esophageal or stomach cancer. The goal is to see if this combination works better and causes fewer side effects than current treatments. About 52 adults with these ca…

This early-phase study tests a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 101 people with certain cancer…

This study tests a new drug combination (telisotuzumab adizutecan, budigalimab, and two standard chemotherapies) as a first treatment for adults with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 participants will r…

This study tests whether combining two or three drugs (cabozantinib, durvalumab, and tremelimumab) can safely shrink tumors in people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that cannot be removed by surgery will …

This early-stage trial tests a drug called sigvotatug vedotin, alone or with other medicines, in people with advanced solid tumors like lung, head and neck, or breast cancer. The main goal is to check safety and find the right dose. About 1,000 participants will join this study t…

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or junction cancer that can be removed. The goal is to see if the combination is safe and works well enough to …

This early-phase study tests a new drug called NRM-823, alone or with an immunotherapy, in 150 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. The study includes several cancer types lik…

This study tests a new medicine (PF-08634404) combined with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new combo t…

This early-phase trial tests adding a precise, MRI-guided radiation treatment after standard chemotherapy for people with esophageal adenocarcinoma. The goal is to find the highest safe radiation dose that can improve tumor control without causing severe side effects like fistula…

This study tests an experimental pill called zongertinib, which blocks HER2—a protein that makes cancer grow. It is for adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and hasn't responded to prior treatments. The study has two parts: first, findi…

This study tests a new combination treatment for people with advanced stomach, esophageal, or gastroesophageal junction cancer that has not responded to standard therapy. Participants receive injections of a cancer-killing virus (OBP-301) directly into their tumor during a scope …

This early-stage study is testing an experimental drug called AZD5863 in adults with advanced stomach, esophageal junction, esophageal, or pancreatic cancers that have spread. The drug is designed to work like a bridge, connecting the patient's own immune cells to cancer cells to…

This study tests a new, office-based method to detect Barrett's esophagus—a condition that can lead to esophageal cancer—in people who do not have chronic heartburn. Participants will answer a questionnaire, swallow a capsule balloon test (EsoCheck), and have a lab analysis (EsoG…

This study tests a pill-sized sponge on a string that people swallow to collect cells from the esophagus. The sample is then checked for signs of Barrett's esophagus, a condition that can lead to cancer. The goal is to see if this simple, low-cost method works as well as a standa…

This study is testing a new, less invasive way to diagnose Barrett's esophagus and early esophageal cancer using a sponge capsule device. Participants swallow the capsule, which collects cells from the esophagus for analysis. The goal is to see if this method is accurate and safe…

This study tests a new way to find early signs of esophageal cancer in people with Barrett's esophagus. Participants will drink or have a topical solution containing two fluorescent dyes that attach to cancer cells, making them glow during a special endoscopy. The goal is to see …

This study tests whether obeticholic acid can prevent esophageal cancer in 30 adults with Barrett's esophagus, a condition that raises cancer risk. The drug works by reducing harmful bile acids that damage the esophagus. Participants take the drug or a placebo for a set time, and…

This study collects tissue samples from 50 adults with Barrett's esophagus who are at risk for esophageal cancer. Researchers will use brush cytology and genetic tests to develop a risk model that could improve surveillance and predict cancer recurrence. Participants undergo two …

This study looks at the best way to manage Barrett's esophagus with low-grade dysplasia, a condition where the esophagus lining has abnormal but not yet cancerous cells. Researchers will compare two common approaches: regular check-ups with biopsies (surveillance) versus a proced…

This study is a registry that collects information on how patients with advanced esophageal, stomach, or gastroesophageal junction cancer are treated in everyday practice in Germany. It will include about 1,900 adults starting their first palliative therapy. The goal is to unders…

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…

This study aims to find out how common Barrett's esophagus is in people with eating disorders who frequently purge (vomit) or ruminate. Researchers will use a simple, non-invasive test on 25 adults admitted to a specialized eating disorder treatment center. The goal is to better …